MDM2 Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2024

Mouse double minute 2 homolog (MDM2), also known as E3 ubiquitin-protein ligase Mdm2, is a protein that is encoded by the MDM2 gene in humans. MDM2 is a protein that plays a crucial role in regulating the tumor suppressor protein p53 activity. MDM2 inhibitors are a class of drugs that specifically target and inhibit the activity of the Mouse double minute 2 homolog (MDM2) protein. These inhibitors have gained significant attention in cancer research and drug development due to their potential to reactivate the tumor suppressor function of the p53 protein. The primary purpose of MDM2 inhibitors is to disrupt the interaction between MDM2 and p53, thereby preventing MDM2 from inhibiting p53's activity and promoting its degradation. By doing so, MDM2 inhibitors can stabilize and activate p53, which in turn can induce cell cycle arrest, DNA repair, and apoptosis in cancer cells. This is particularly relevant because the p53 pathway is frequently disrupted in cancer, either through mutations in the p53 gene itself or through overexpression or amplification of MDM2.

MDM2 Inhibitors are used to treat acute myelogenous leukemia, lymphoma, sarcoma, chronic myeloid leukemia, acute lymphocytic leukemia, neuroendocrine tumors, and neutropenia. Moreover, the increasing prevalence of leukemia and lymphoma and increasing R&D investments are the key drivers for the MDM2 Inhibitors market. For instance, according to the World Cancer Research Fund 2020, There were an estimated 18.1 million cancer cases around the world and 4,74,519 new cases of Leukaemia in 2020. The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020. Moreover, the development of novel molecules by many market players is coming up to overcome challenges in therapy. For instance, Roche's Milademetan (RAIN-32) for treating Liposarcoma is under the various stages of clinical studies.

Key Market Developments:

• In May 2023, Rain Oncology completed phase 3, a randomized multicenter study of Milademetan versus Trabectedin in patients with dedifferentiated liposarcoma.

Drugs under the Pipeline for MDM2 Inhibitors:

Navtemadlin (KRT-232)

Idasanutlin (RG7388)

Siremadlin (HDM201)

Milademetan (RAIN-32)

Alrizomadlin (APG-115)

RG7112

Brigimadlin (BI 907828)

ALRN-6924

EP-101 STEMVAC

MI-773

MK-8242

ASTX295

CGM097

RG7775

Serdemetan (JNJ-26854165)

Clinical Activity and Developments of MDM2 Inhibitors:

Till July 2023, more than four companies have approximately 15 molecules targeting the many cancers. For these molecules, more than 50 clinical trials are being conducted and the majority are in phase-2, and phase-3 clinical trials by the players across the globe. For instance,

• In April 2022, Roche has conducting a phase 1/2 trial of Idasanutlin in combination with Ixazomib and Dexamethasone in patients with 17p deleted, relapsed multiple myeloma.